Adoptive cell therapy using T-cell receptor (TCR)–engineered T cells is a clinically feasible and promising approach to target tumors, but is currently faced with compromised antitumor efficacies in patients. Here, we extensively validated immune-deficient mice to facilitate further development of the therapeutic potential of TCR-engineered T cells. Treatment of human melanoma-bearing SCID or NSG mice with high doses of human T cells transduced with an hgp100/HLA-A2-specific TCR did not result in antitumor responses irrespective of chemotherapeutic preconditioning. Imaging of human green fluorescent protein–labeled T cells demonstrated significant T-cell accumulation in intratumoral vasculature directly upon T-cell transfer, which was followed by loss of T cells within 72 hr. Peripheral persistence of human T cells was highly compromised and appeared related to T-cell differentiation. On the contrary, adoptive transfer (AT) of relatively low numbers of hgp100/HLA-A2 TCR-transduced mouse T cells resulted in rapid clearance of large established human melanomas. Unexpectedly and in contrast to reported studies with chimeric antibody receptor–engineered T cells, antitumor activity and homeostatic expansion of T cells were independent of TCR transgene as evidenced in two SCID strains and using two different human melanoma cell lines. Interestingly, the xeno-reactive melanoma response of mouse T cells appeared to be dictated by CD4+ tumor-infiltrating lymphocytes and did not require in vitro T-cell activation, retroviral gene transfer, or subcutaneous interleukin-2 support. Taken together, AT of human but not mouse T cells in human melanoma-bearing immune-deficient mice is in close accordance with clinical studies.
Get full access to this article
View all access options for this article.
References
1.
AppayV., van LierR.A., SallustoF., RoedererM.2008. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A, 73:975–983.
BergerC., JensenM.C., LansdorpP.M.et al.2008. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest., 118:294–305.
4.
BobisseS., RondinaM., MerloA.et al.2009. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res., 69:9385–9394.
5.
BrentjensR.J., LatoucheJ.B., SantosE.et al.2003. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med., 9:279–286.
6.
BrentjensR.J., SantosE., NikhaminY.et al.2007. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res., 13:5426–5435.
7.
ButlerM.O., FriedlanderP., MilsteinM.I.et al.2011. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci. Transl. Med., 3:80ra34.
8.
CarpenitoC., MiloneM.C., HassanR.et al.2009. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U.S.A., 106:3360–3365.
9.
CheadleE.J., GilhamD.E., HawkinsR.E.2008. The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br. J. Haematol., 142:65–68.
10.
ChekmasovaA.A., RaoT.D., NikhaminY.et al.2010. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res., 16:3594–3606.
11.
ClayT.M., CusterM.C., SachsJ.et al.1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol., 163:507–513.
12.
CraddockJ.A., LuA., BearA.et al.2010. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother., 33:780–788.
13.
DarcyP.K., HaynesN.M., SnookM.B.et al.2000. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J. Immunol., 164:3705–3712.
14.
de WitteM.A., BendleG.M., van den BoomM.D.et al.2008a. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J. Immunol., 181:2563–2571.
15.
de WitteM.A., JorritsmaA., KaiserA.et al. (2008b). Requirements for effective antitumor responses of TCR transduced T cells. J. Immunol., 181:5128–5136.
16.
DudleyM.E., WunderlichJ.R., YangJ.C.et al.2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol., 23:2346–2357.
17.
FriedmanT., ShimizuA., SmithR.N.et al.1999. Human CD4+ T cells mediate rejection of porcine xenografts. J. Immunol., 162:5256–5262.
18.
GadeT.P., HassenW., SantosE.et al.2005. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res., 65:9080–9088.
19.
HansonH.L., DonermeyerD.L., IkedaH.et al.2000. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity, 13:265–276.
20.
HaynesN.M., SnookM.B., TrapaniJ.A.et al.2001. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs FcɛRI-γJ. Immunol., 166:182–187.
21.
HaynesN.M., TrapaniJ.A., TengM.W.et al.2002a. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J. Immunol., 169:5780–5786.
22.
HaynesN.M., TrapaniJ.A., TengM.W.et al.2002b. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood, 100:3155–3163.
23.
HinrichsC.S., BormanZ.A., CassardL.et al.2009. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. U.S.A., 106:17469–17474.
24.
HuangJ., KhongH.T., DudleyM.E.et al.2005. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother., 28:258–267.
25.
HwuP., YangJ.C., CowherdR.et al.1995. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res., 55:3369–3373.
26.
JohnsonL.A., MorganR.A., DudleyM.E.et al.2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 114:535–546.
27.
KalosM., LevineB.L., PorterD.L.et al.2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3:95ra73.
28.
KanekoS., MastaglioS., BondanzaA.et al.2009. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood, 113:1006–1015.
29.
KershawM.H., WestwoodJ.A., ParkerL.L.et al.2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res., 12:6106–6115.
30.
KesselsH.W., WolkersM.C., van den BoomM.D.et al.2001. Immunotherapy through TCR gene transfer. Nat. Immunol., 2:957–961.
31.
KowolikC.M., ToppM.S., GonzalezS.et al.2006. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res., 66:10995–11004.
32.
LamersC.H., SleijferS., VultoA.G.et al.2006a. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol., 24:e20–e22.
33.
LamersC.H., WillemsenR.A., van ElzakkerP.et al.2006b. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer. Cancer Gene Ther., 13:503–509.
34.
MiloneM.C., FishJ.D., CarpenitoC.et al.2009. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther., 17:1453–1464.
35.
MorganR.A., DudleyM.E., WunderlichJ.R.et al.2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314:126–129.
36.
MorrisE.C., TsalliosA., BendleG.M.et al.2005. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. U.S.A., 102:7934–7939.
37.
ParkhurstM.R., YangJ.C., LanganR.C.et al.2011. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther., 19:620–626.
38.
PiersonR.N.3rd, WinnH.J., RussellP.S., AuchinclossH.Jr.1989. Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. J. Exp. Med., 170:991–996.
39.
PinthusJ.H., WaksT., Kaufman-FrancisK.et al.2003. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res., 63:2470–2476.
40.
PinthusJ.H., WaksT., MalinaV.et al.2004. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest., 114:1774–1781.
41.
PorterD.L., LevineB.L., KalosM.et al.2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365:725–733.
42.
PouwN., Treffers-WesterlakenE., KraanJ.et al.2010a. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol. Immunother., 59:921–931.
43.
PouwN., Treffers-WesterlakenE., MondinoA.et al.2010b. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Mol. Immunol., 47:1411–1420.
44.
PouwN.M., WesterlakenE.J., WillemsenR.A., DebetsR.2007. Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes. J. Gene Med., 9:561–570.
45.
RobbinsP.F., DudleyM.E., WunderlichJ.et al.2004. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol., 173:7125–7130.
46.
RobbinsP.F., MorganR.A., FeldmanS.A.et al.2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol., 29:917–924.
47.
SavoldoB., RooneyC.M., Di StasiA.et al.2007. Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood, 110:2620–2630.
48.
SchaftN., WillemsenR.A., de VriesJ.et al.2003. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCRαβ genes into primary human T lymphocytes. J. Immunol., 170:2186–2194.
49.
SchaftN., LankiewiczB., DrexhageJ.et al.2006. T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFN-γ production. Int. Immunol., 18:591–601.
50.
SeynhaeveA.L., HovingS., SchipperD.et al.2007. Tumor necrosis factor α mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res., 67:9455–9462.
51.
ShultzL.D., LyonsB.L., BurzenskiL.M.et al.2005. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells. J. Immunol., 174:6477–6489.
52.
SmythM.J., KershawM.H., TrapaniJ.A.1997. Xenospecific cytotoxic T lymphocytes: potent lysis in vitro and in vivo. Transplantation, 63:1171–1178.
53.
SongD., YeQ., CarpenitoC.et al.2011. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)Cancer Res., 71:4617–4627.
54.
TengM.W., KershawM.H., MoellerM.et al.2004. Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Human Gene Ther., 15:699–708.
55.
Van de GriendR.J., Van KrimpenB.A., BolS.J.et al.1984. Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat-labile serum component and by various types of feeder cells. J. Immunol. Methods, 66:285–298.
56.
WangX., BergerC., WongC.W.et al.2011. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood, 117:1888–1898.
57.
WestwoodJ.A., SmythM.J., TengM.W.et al.2005. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl. Acad. Sci. U.S.A., 102:19051–19056.
58.
WillemsenR.A., WeijtensM.E., RonteltapC.et al.2000. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther., 7:1369–1377.
59.
XueS.A., GaoL., HartD.et al.2005. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood, 106:3062–3067.
60.
XueS.A., GaoL., ThomasS.et al.2010. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica, 95:126–134.
61.
ZhaoY., WangQ.J., YangS.et al.2009. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol., 183:5563–5574.
62.
ZhaoY., MoonE., CarpenitoC.et al.2010. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res., 70:9053–9061.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
